Non-Adoption is Your Biggest Risk.
Technical and regulatory success is only half the battle. Research from Harvard Business School confirms that most failures in MedTech, Pharma, and Digital Health are not due to engineering flaws, but a failure to overcome "Adoption Barriers".
Identifying the Three Critical Adoption Risks.
"Blind Identification."
Critical insights rarely survive the engineering transition.
You risk identifying the wrong opportunity, lacking real-world impact and perceived value.
THE CLINICAL RISK
"Frictional Workflows."
Fragmented workflows isolate engineering from clinical reality.
You engineer a solution that passes V&V but remains "shelfware" because it ignores clinical workflows.
THE R&D RISK
"Invisible Evidence."
Design validation is treated as a regulatory hurdle rather than sales empowerment.
Without adoption-ready evidence, your product is invisible to payers and clinicians.
THE COMMERCIAL RISK
A Methodology for Real-World Impact.
Upstream
Aligning clinical requirements with early market fit from the start, reducing risk and driving real-world adoption.
Core
By creating a robust solution and establishing clear safety and usability evidence, you de-risk your launch and pave the way for smooth adoption.
Downstream
Ensuring sustained use through therapy adherence support & operational stability allows you to maximize revenue.
THE CLINICAL RISK
THE R&D RISK
THE COMMERCIAL RISK
"Blind Identification."
Critical insights rarely survive the engineering transition.
You risk identifying the wrong opportunity, lacking real-world impact and perceived value.
"Frictional Workflows.
Fragmented workflows isolate engineering from clinical reality.
You engineer a solution that passes V&V but remains "shelfware" because it ignores clinical workflows.
"Invisible Evidence."
Design validation is treated as a regulatory hurdle rather than sales empowerment.
Without adoption-ready evidence, your product is invisible to payers and clinicians.